AI Article Synopsis
- The study aimed to assess the effectiveness of upadacitinib compared to placebo and adalimumab on patient-reported outcomes in individuals with rheumatoid arthritis (RA) who didn't respond adequately to methotrexate (MTX).
- Over 48 weeks, various patient-reported outcomes, including pain, disability, and overall disease activity, were evaluated, showing significant improvements with upadacitinib treatment compared to placebo and similar outcomes versus adalimumab.
- The results indicated that upadacitinib not only outperformed placebo across all measured outcomes but also provided meaningful improvements in quality of life and symptom management when compared to adalimumab after 12 weeks of treatment, and these benefits were sustained over
Article Abstract
Objective: To evaluate the impact of upadacitinib vs placebo and adalimumab treatment, on patient-reported outcomes (PROs) in SELECT-COMPARE in an active RA population with inadequate responses to MTX (MTX-IR).
Methods: PROs in patients receiving upadacitinib (15 mg QD), placebo, or adalimumab (40 mg EOW) while on background MTX were evaluated over 48 weeks. PROs included Patient Global Assessment of Disease Activity (PtGA) and pain by visual analogue scale (VAS), the HAQ Disability Index (HAQ-DI), the 36-Item Short Form Survey (SF-36), morning (AM) stiffness duration and severity, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and work instability. Least squares mean (LSM) changes and proportions of patients reporting improvements ≥ minimal clinically important differences (MCIDs) and scores ≥ normative values were evaluated.
Results: Upadacitinib and adalimumab resulted in greater LSM changes from baseline vs placebo across all PROs (P < 0.05) at week 12, and pain and AM stiffness severity (P < 0.05) at week 2. More upadacitinib- vs placebo-treated (P < 0.05) and similar percentages of upadacitinib- vs adalimumab-treated patients reported improvements ≥ MCID across all PROs at week 12. Upadacitinib vs adalimumab resulted in greater LSM changes from baseline in PtGA, pain, HAQ-DI, stiffness severity, FACIT-F, and the SF-36 Physical Component Summary (PCS) (all P < 0.05) at week 12. More upadacitinib- vs adalimumab-treated patients reported scores ≥ normative values in HAQ-DI and SF-36 PCS (P < 0.05) at week 12. More upadacitinib- vs adalimumab-treated patients maintained clinically meaningful improvements in PtGA, pain, HAQ-DI, FACIT-F, and AM stiffness through 48 weeks.
Conclusion: In MTX-IR patients with RA, treatment with upadacitinib resulted in statistically significant and clinically meaningful improvements in PROs equivalent to or greater than with adalimumab.
Trial Registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02629159.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645276 | PMC |
| http://dx.doi.org/10.1093/rheumatology/keab158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- * The study evaluates the effectiveness and safety of various treatments for non-radiographic axial spondyloarthritis (nr-axSpA), including tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i), and Janus kinase inhibitors (JAKi).
- * A systematic review covered 10 randomized controlled trials with 2,418 participants, utilizing multiple databases and statistical software to analyze data on treatment efficacy and adverse events.
- * Results showed that certolizumab pegol was the most effective, followed by other treatments like golimumab and bimekizumab, with most therapies significantly improving symptoms compared to placebo; however, safety profiles varied among treatments.
A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease.
Australas J Dermatol
December 2024
Department of Dermatology, Skin Health Institute, Melbourne, Victoria, Australia.
This study systematically reviews existing data on the efficacy of Tyrosine Kinase 2 (TYK2) inhibitors in comparison to placebo or standard treatments for therapeutic benefit and improving quality of life in dermatological diseases. Seventeen records representing 13 clinical trials, one matching-adjusted indirect comparison, and one case study were included. Results indicate that Deucravacitinib is superior to placebo, Apremilast and Adalimumab in treating adult patients with moderate-to-severe plaque psoriasis and superior to placebo in the treatment of adults with systemic lupus erythematosus.
View Article and Find Full Text PDFRisk of Malignancy Related to Ixekizumab in Patients in Patients With Psoriatic Arthritis or Axial Spondyloarthropathy: Systematic Review and Meta-analysis.
J Clin Rheumatol
December 2024
Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, Medical School, Universidad de Santiago de Compostela.
Article Synopsis
- The study evaluated the malignancy risk linked to ixekizumab in patients with rheumatological conditions through a systematic review of randomized controlled trials (RCTs) and long-term extension studies (LTEs).
- Meta-analyses indicated a low overall risk of malignancy, with Peto odds ratios showing varied results when compared to placebo and another drug, adalimumab.
- The research concluded that while ixekizumab generally poses a low risk for malignancy, certain conditions, like nonmelanoma skin cancer, may be exceptions for patients with psoriatic arthritis and axial spondyloarthritis.
Development of Extra-Musculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.
Arthritis Rheumatol
December 2024
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Article Synopsis
- The study aimed to evaluate the occurrence of extra-musculoskeletal manifestations (EMMs) in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with a specific medication, upadacitinib (UPA15).
- Data from five clinical trials were analyzed to compare adverse events like uveitis and inflammatory bowel disease (IBD) among patients receiving either UPA15, a placebo, or adalimumab (ADA).
- Results showed that most patients did not have a history of EMMs, and the occurrence of uveitis and IBD was generally low, particularly in those treated with UPA15 compared to the placebo.
The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib.
Rheumatol Ther
November 2024
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Introduction: While modern treatments can prevent progressive bone destruction in patients with rheumatoid arthritis (RA) achieving clinical remission, it is unclear whether residual clinical activity may cause or be associated with progressive joint damage. This post hoc analysis evaluated the association between clinical disease activity and structural progression in patients with RA treated with filgotinib (FIL) in FINCH 1 (NCT02889796).
Methods: Patients with RA and inadequate response to methotrexate (MTX) use were randomized 3:3:2:3 to FIL 200 mg (FIL200) or FIL 100 mg (FIL100) once daily, adalimumab 40 mg biweekly, or placebo, all with background MTX.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!